Insights

Surgeons attend a cadaveric lab. They preceptor with a KOL. They schedule a first case. They go routine — or they fall off the funnel. Most mid-market spine companies track this in Excel and call it CRM. The cost is invisible until you add it up.

On February 2, 2026, the FDA's new Quality Management System Regulation became enforceable. For ISO 13485-certified companies, the transition was supposed to be a paperwork exercise. For everyone else, it's a fire drill. Why this matters more than your team is telling you, and where AI actually helps.

New reps take 9-12 months to hit quota in medical device sales. For a mid-market spine or ortho company hiring 6-12 reps a year, that's millions in lost contribution margin. Why classroom training has plateaued and what an AI-augmented onboarding system actually looks like.

Complaint handling is one of the top three FDA observations year after year. The backlog is almost always invisible until the auditor knocks. Why mid-market companies are uniquely exposed in 2026, and what AI-augmented complaint triage actually does that a QMS platform alone cannot.

PE-backed device platforms are betting on bolt-on acquisitions to drive multiple expansion. The smarter portfolios are quietly investing in operational leverage instead — and the math is more favorable than the deck team is showing the LP.

Mid-market device companies run on a mix of W2 reps, 1099 contractors, and exclusive distributors. The reporting fragments at the boundary. Why most companies cannot answer the basic question "who is selling our product right now?" and what to do about it.

A small number of mid-market device companies are deploying operational AI across functions and producing measurable improvements in rep productivity, regulatory cycle times, surgeon adoption rates, and quality efficiency. Almost none of them are talking about it. Why the most important trend in this industry is happening underneath the surface — and why the discourse about AI in medtech is therefore systematically wrong.

The competitive landscape in mid-market medtech is about to sort. Companies who deploy operational AI well between now and 2028 will compound advantages their competitors cannot catch. Companies who wait will discover the gap when it is too late to close it. An argument about timing, and what specifically to do across every major function of your company before the window closes.